Navigation Links
MabVax Therapeutics Initiates Phase II Clinical Trial of Vaccine to Prevent Recurrent Sarcoma
Date:7/22/2010

SAN DIEGO, July 22 /PRNewswire/ -- MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that the first patients have been enrolled in a Phase II clinical trial aimed at assessing the efficacy and safety of its vaccine to prevent or delay the recurrence of sarcoma. The clinical trial will enroll 126 metastatic sarcoma patients, 16 years or older in a randomized, multicenter, double-blind Phase II study of a trivalent vaccine specifically developed to target and kill residual circulating cancer cells and micrometastases thought to cause recurrent cancer.  

In the United States (US), there are approximately 13,200 sarcoma cases diagnosed each year, representing less than 1% of all new cancers.  Prognosis remains poor, with more than 5,200 patients in the US dying of disease each year.  As in other malignancies, disease recurrence and metastasis are common in sarcoma.  Despite undergoing potentially curative surgical resection or combination therapy, the majority of these patients with recurrent sarcoma die as a result of further recurrences.  The addition of chemotherapy to surgical resection has not shown to improve outcome in adult patients with sarcoma. Thus, in the majority of cases, the current standard of care following treatment of metastatic disease and the achievement of disease-free status is expectant management.

The vaccine is a trivalent ganglioside vaccine administered with an immunological adjuvant in a series of 10 subcutaneous injections given over an 84-week period.  The vaccine is intended to instruct the patient's immune system to make antibodies against the three ganglioside ant
'/>"/>

SOURCE MabVax Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Echo Therapeutics, Inc. (NASDAQ: ... skin permeation, continuous glucose monitoring and associated technologies, ... has been appointed Chief Executive Officer effective December ... years of experience in the medical device, pharmaceutical ... as Vice President, Business Development, Otsuka Pharmaceuticals as well ...
(Date:12/24/2014)... , Dec. 23, 2014   Synageva ... a biopharmaceutical company developing therapeutic products for rare ... Agency (EMA) of the Marketing Authorization Application (MAA) ... recently granted the company,s request for accelerated assessment, ... regulatory review time.   The MAA, ...
(Date:12/24/2014)... 2014 Tianyin Pharmaceutical Co., Inc. (NYSE ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... that the Company achieved the Public Notice (Gong ... certificate of TPI,s Qionglai Facility (QLF) from the ... notice period is a significant procedure of GMP ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3
... Major Lupin Limited announced today that its U.S. subsidiary, ... Award by the Healthcare Distribution Management Association (HDMA) for ... with sales of up to $100 million in the ... winners are selected by HDMA Distributor members to recognize ...
... Laboratories, a leading provider of medication monitoring services to ... hiring of Martin Price as General Counsel and Janna ... Officer. As Millennium Laboratories General Counsel, Mr. ... Howard Appel , Millennium Laboratories, President, said, "We ...
Cached Medicine Technology:HDMA Honors Lupin with DIANA Award for Best Overall Generic Manufacturer 2HDMA Honors Lupin with DIANA Award for Best Overall Generic Manufacturer 3Millennium Laboratories Announces New General Counsel Martin Price and Chief Compliance Officer Janna Sipes 2Millennium Laboratories Announces New General Counsel Martin Price and Chief Compliance Officer Janna Sipes 3
(Date:12/26/2014)... CA (PRWEB) December 26, 2014 ... score of 3.1 out of 5. This score reflects ... low level of product specialization, low switching costs and ... is reduced by the low availability of substitutes for ... world price of steel and aluminum, key inputs in ...
(Date:12/26/2014)... December 26, 2014 Plugin and template developers ... Volume 5 Plugin for Final Cut Pro X. , “TransPack ... light tool to pull off an industry professional look” Said ... their hands on TransPack Volume 5, a new level of ... a set of over 50 Final Cut Pro X transitions ...
(Date:12/26/2014)... Philadelphia, PA (PRWEB) December 26, 2014 ... to Work in the state of Pennsylvania for 2014. ... the first statewide programs of its kind in the ... Pennsylvania Foundation, the Pennsylvania Department of Community and Economic ... Human Resource Management and the Central Penn Business Journal. ...
(Date:12/25/2014)... The microscopy market is estimated to grow at ... by 2019. Optical microscopy is the largest segment ... segment is expected to show the fastest growth ... nanotechnology, technological advancements, and increasing federal support to ... Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 ... Market Analysis to 2023” focuses on the current ... opportunities in the colorectal cancer market. Stivarga is ... of colon or rectal cancer. Boehringer Ingelheim is ... for the treatment of refractory CRC in the ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... Sept. 11 NBTY, Inc. (NYSE:,NTY) (http://www.NBTY.com ), ... announced that it will web cast the,presentation by Harvey ... CL King Best Ideas Conference in New York on ... be web cast live on NBTY,s web site, (http://www.nbty.com ...
... 11 If you,ve purchased prescription,drugs sometime ... receive some money as,part of a multi-million ... from the AWP Track 2 Settlement Administrator ... access video, audio, text, graphics and,photos for ...
... Black lung disease is not a problem of the ... die from it and associated ailments. , In response, ... R. Saylor, associate professor of mechanical engineering at Clemson ... reducing harmful particulate levels in coal mines. Saylor,s research ...
... Sept. 11 A US House Government,Oversight subcommittee ... a mandatory requirement, to reduce mercury emissions. The,Mercury ... at two,congressional hearings over the past several months ... Subcommittee report found that the best way to ...
... Sept. 11 Wolters Kluwer Health, a,division ... information and business,intelligence for students, professionals, and ... the pharmaceutical industry, announced,today the appointment of ... & Education Unit., Lubeck comes to ...
... docs, says researcher , , THURSDAY, Sept. 11 (HealthDay News) -- ... be the last place you would have a discussion about ... a conversation. , Almost half of those included in ... that prayer was very important to their sense of well-being, ...
Cached Medicine News:Health News:NBTY to Web Cast Presentation at CL King Best Ideas Conference 2Health News:CDC awards Clemson researcher $700,000 to study black lung prevention 2Health News:To Reduce Mercury Pollution, 'Dentists need a mandatory requirement,' According to US House Oversight Report; Mercury Group Concurs 2Health News:Wolters Kluwer Health Appoints Scott Lubeck Vice President, Technology of its Professional & Education Unit 2Health News:Spiritual Beliefs Part of Health Care for Some 2Health News:Spiritual Beliefs Part of Health Care for Some 3
Implantable medical grade silicone end cap for insulation and sealing protection of 5 mm or 3.2 mm connectors....
...
... Renewal 3 cardiac resynchronization therapy ... and cardiac resynchronization therapy. Features: ... and left ventricular (LV) pacing ... irregular ventricular intervals during conducted ...
... housing. MRI-compatible. Requires a guide sphere ... a standard 1.0 - 1.5 cm burr ... assembly with a white collar. MRI-compatible. ... Sterile; single-use only Guide sphere assembly with ...
Medicine Products: